Falcon Point Capital’s BioLife Solutions BLFS Stock Holding History

Falcon Point Capital’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-11,091	Closed	-$105K	–	70
2020 Q1	$105K	Sell	11,091 -1,571	-12%	-$21.6K	0.23%	92
2019 Q4	$205K	Hold	12,662	–	–	0.26%	100
2019 Q3	$215K	Buy	+12,662	New	+$238K	0.12%	94

Other funds holding BLFS

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

SPA

Sentinel Pension Advisors Wakefield, Massachusetts $676M AUM 15.31% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Tarsadia Capital New York $5.64M AUM 15.7% 1-Year Est. Return

Falcon Point Capital's BLFS Position: Q2 2020 in Review

Falcon Point Capital sold out of BioLife Solutions (BLFS) in Q2 2020, closing a stake of 11,091 shares — an estimated $105K sold.

Falcon Point Capital first reported a position in BLFS in Q3 2019 and held it in 3 quarters. The position peaked at $215K in Q3 2019. 82 funds tracked by Wall St. Rank hold BLFS as of Q2 2020.

Falcon Point Capital reported no remaining BioLife Solutions position as of Q2 2020 after selling out during the quarter.
Falcon Point Capital sold 11,091 BioLife Solutions shares in Q2 2020, an estimated $105K.
Falcon Point Capital first reported a position in BioLife Solutions in Q3 2019 and held it in 3 quarters.
Falcon Point Capital's BioLife Solutions position peaked at $215K in Q3 2019.
82 funds tracked by Wall St. Rank held BioLife Solutions as of Q2 2020.

Based on Falcon Point Capital's 13F filing for Q2 2020, filed 21 Jul 2020.